Opentrons raises $40M to scale AI-driven lab robotics

Opentrons Labworks, a startup specializing in AI-powered robotic lab automation, has raised $40 million in a Series E round led by healthcare investor Avego, with participation from BroadOak Capital Partners. The funding will support scaling the company’s robotics, software, and data infrastructure tools, which aim to standardize repetitive laboratory tasks.

Founded in 2014, Opentrons designs benchtop robots that handle liquid transfers, sample preparation, and other manual lab work. Its flagship products—the Flex and OT-2—automate pipetting, PCR, DNA extraction, protein purification, and ELISA assays, processes traditionally performed by scientists. The Flex, the more advanced model, includes a robotic gripper for moving lab plates, reducing human intervention in multi-step experiments. The OT-2, a smaller and less expensive option, focuses on liquid-handling tasks for labs with narrower automation needs.

The startup has gained significant adoption among research institutions and pharmaceutical companies, suggesting its systems are filling a critical gap in lab efficiency. Industry observers note that as AI reshapes scientific discovery, the physical execution of experiments has become a limiting factor. Opentrons argues that its robots, paired with AI software, can address this by enabling more autonomous workflows. The company’s approach emphasizes accessibility, positioning its hardware as a plug-and-play solution for labs without specialized infrastructure.

Opentrons’ expansion comes amid broader investment in lab automation. When StartupReader covered a $75 million raise for a drug manufacturing robotics startup in October 2026, the focus was on precision medicine production. Opentrons, by contrast, targets a wider range of routine lab tasks rather than niche applications. Its modular, benchtop design also sets it apart from humanoid robot startups like Maven Robotics, which are still in early pilot phases for industrial use.

The startup’s traction with major industry players indicates strong demand for scalable automation. However, the market is crowded, with competitors ranging from dedicated lab automation firms to broader robotics companies. Opentrons’ challenge will be demonstrating that its hardware and software can outperform alternatives in reliability, ease of use, and seamless integration with AI-driven workflows.

What’s next will hinge on execution. If Opentrons can deliver on its vision of “autonomous science,” it could solidify its role as a standard in lab automation. But if competitors introduce more advanced or specialized solutions, the startup’s early advantage may erode. For now, the $40 million funding round reflects investor confidence in its potential to make lab robots a mainstream tool for scientific research.

Sources: siliconangle.com